Certara (NASDAQ:CERT) Issues Quarterly Earnings Results

Certara (NASDAQ:CERT) announced its earnings results on Wednesday. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.02, Briefing.com reports. The firm had revenue of $94.80 million for the quarter, compared to the consensus estimate of $95.51 million. Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The firm’s revenue for the quarter was up 10.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.06 EPS. Certara updated its FY24 guidance to $0.41-0.44 EPS and its FY 2024 guidance to 0.410-0.440 EPS.

Certara Price Performance

Shares of CERT traded up $0.04 during midday trading on Friday, reaching $11.03. The stock had a trading volume of 1,081,810 shares, compared to its average volume of 786,430. Certara has a 52 week low of $9.99 and a 52 week high of $19.87. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.61 and a quick ratio of 2.61. The firm’s 50 day moving average price is $11.02 and its 200-day moving average price is $13.70. The company has a market capitalization of $1.77 billion, a P/E ratio of -22.06, a P/E/G ratio of 4.88 and a beta of 1.51.

Analyst Ratings Changes

CERT has been the topic of several recent analyst reports. Barclays cut their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday. Robert W. Baird cut their target price on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday. Finally, UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Friday, September 27th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Certara has an average rating of “Hold” and a consensus target price of $15.92.

Insider Transactions at Certara

In related news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares in the company, valued at $1,125,658.16. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now owns 50,091 shares in the company, valued at approximately $552,503.73. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the transaction, the insider now owns 99,704 shares in the company, valued at $1,125,658.16. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.39% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.